{"abstract": "The idea of a corporate split comes up often in the drug industry but rarely happens. But Amgen\u2019s drug focus and the banker background of its C.E.O. give the notion a chance, Robert Cyran of Reuters Breakingviews writes.", "web_url": "https://dealbook.nytimes.com/2014/10/22/amgens-boss-makes-a-prime-target-for-a-breakup/", "snippet": "The idea of a corporate split comes up often in the drug industry but rarely happens. But Amgen\u2019s drug focus and the banker background of its C.E.O. give the notion a chance, Robert Cyran of Reuters Breakingviews writes.", "lead_paragraph": "Amgen\u2019s boss makes a prime breakup target for Daniel S. Loeb. The chief executive, Robert Bradway, a former Morgan Stanley banker, has run the $109 billion biotechnology company for the last two years. The idea of splitting such companies into a cash cow and a growth arm comes up often, but rarely happens. Amgen may be the exception.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/22/business/dbpix-loeb1/dbpix-loeb1-articleLarge.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/10/22/business/dbpix-loeb1/dbpix-loeb1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/22/business/dbpix-loeb1/dbpix-loeb1-jumbo.jpg", "height": 683, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/22/business/dbpix-loeb1/dbpix-loeb1-superJumbo.jpg", "height": 1365, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/22/business/dbpix-loeb1/dbpix-loeb1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/10/22/business/dbpix-loeb1/dbpix-loeb1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/10/22/business/dbpix-loeb1/dbpix-loeb1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Amgen\u2019s Boss Makes a Prime Breakup Target for Loeb", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Biotechnology and Bioengineering", "rank": 1, "major": "N"}, {"name": "persons", "value": "Bradway, Robert A", "rank": 2, "major": "N"}, {"name": "persons", "value": "Loeb, Daniel S", "rank": 3, "major": "N"}, {"name": "organizations", "value": "AMGEN INC", "rank": 4, "major": "N"}], "pub_date": "2014-10-22T15:46:26+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Robert Cyran", "person": [{"firstname": "Robert", "middlename": null, "lastname": "Cyran", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/363e6bcc-ba94-56e5-91c1-f71aceaf6684", "word_count": 395, "uri": "nyt://article/363e6bcc-ba94-56e5-91c1-f71aceaf6684"}